STOCK TITAN

Oncternal Therapeutics Inc - ONCT STOCK NEWS

Welcome to our dedicated news page for Oncternal Therapeutics (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncternal Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncternal Therapeutics's position in the market.

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provided a business update and reported third quarter 2023 financial results. They announced the dosing of the first patient in the Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor, for advanced prostate cancer treatment. They also treated additional patients in the ongoing Phase 1/2 study for ONCT-808, an autologous CAR T cell therapy, for aggressive B-cell lymphoma. The company has $40.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023, with a cash runway projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report Q3 2023 financial results on November 9, 2023, after the U.S. financial markets close. The management will host a webcast at 2:00 p.m. PT to provide a business update and discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics receives Fast Track designation from FDA for ONCT-534 in the treatment of mCRPC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
Rhea-AI Summary
Oncternal Therapeutics adds Dr. Matthew Smith to its Prostate Cancer Scientific Advisory Board to guide the clinical development of ONCT-534, a dual-acting androgen receptor inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management
-
Rhea-AI Summary
Oncternal Therapeutics announces dosing of first patient in Phase 1/2 study of ONCT-534
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Oncternal Therapeutics establishes Prostate Cancer Scientific Advisory Board (SAB) to support the development of its dual-acting androgen receptor inhibitor, ONCT-534. Members of the SAB include world-renowned leaders in prostate cancer research. This development could positively impact the company's stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
management
Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company, has obtained FDA IND clearance for ONCT-534, a dual-action androgen receptor inhibitor for the treatment of advanced prostate cancer. They have also dosed the first patient in their Phase 1/2 study for ONCT-808, a ROR1-targeting autologous CAR T cell therapy for aggressive B-cell lymphoma. The company has extended its cash runway into 2025 with $45.5 million in cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) to Report Q2 2023 Financial Results and Host Webcast for Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
-
Rhea-AI Summary
Oncternal Therapeutics receives FDA authorization for Phase 1/2 study of ONCT-534 in metastatic castration-resistant prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Oncternal Therapeutics Inc

Nasdaq:ONCT

ONCT Rankings

ONCT Stock Data

27.82M
2.65M
8.75%
16.13%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ONCT

oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic